The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

By T. Waldmann. Nature reviews. Immunology, 2006

1,171 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/26b49824fbc9b3c62053a7cfc141c8fa40cbb88b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

Citations in the corpus

Interleukin 12: still a promising candidate for tumor immunotherapy? (2014, background): “Thus, IL-15 seems to function under normal circumstances as a cell-bound cytokine and is trans-presented to responding cells together with co-stimulatory signals ([46] and reviewed in [55]), although the dominance of trans-presentation of IL-15 to CD8 T cells has recently been called into question [”
Dendritic-cell-based therapeutic cancer vaccines. (2013, background): “…upon encounter with DCs presenting tumor-derived peptides (Bousso and Robey, 2003) (Figure 2) in the context of costimulation through CD80, CD70, and 4-1BB (Shuford et al., 1997), as well as DC-derived cytokines such as IL-12 and IL-15 (Araki et al., 2010; Waldmann, 2006; Zhang and Bevan, 2011).”
Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy (2013, neutral): “However, unlike the relatively high-affinity binding of IL-15 to IL-15Ra (Waldmann, 2006), IL-2 binds with relatively low affinity to IL-2Ra with rapid on and off rates, as noted above.”
The role of interleukin-2 during homeostasis and activation of the immune system (2012, background): “Signal transduction occurs via several intracellular pathways, including the Janus kinase (JAK)–STAT pathway, the phosphoinositide 3-kinase (PI3K)–AKT pathway and the mitogen-activated protein kinase (MAPK) pathwa”
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. (2015, background): “Both cytokines stimulate proliferation of T cells, induce generation of cytotoxic lymphocytes (CTLs), and stimulate prolonged expansion of natural killer (NK) cells.(8,12-14) However, in many adaptive immune responses, IL-2 and IL-15 have distinct roles.”
Pre-activation with IL-12, IL-15, and IL-18 induces CD25 and a functional high affinity IL-2 receptor on human cytokine-induced memory-like NK cells (2014, background): “This CD25 expression resulted in a signalcompetent high-affinity IL-2Rabg that stimulated STAT5 phosphorylation in NK cells.”